Skip to main content
Top
Gepubliceerd in:

27-01-2016 | Original Paper

Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home

Auteurs: Lisa M. Ruiz, Mackenzie Damron, Kyle B. Jones, Dean Weedon, Paul S. Carbone, Amanda V. Bakian, Deborah A. Bilder

Gepubliceerd in: Journal of Autism and Developmental Disorders | Uitgave 6/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

This study describes antipsychotic use and metabolic monitoring rates among individuals with developmental disabilities enrolled in a subspecialty medical home (N = 826). Four hundred ninety-nine participants (60.4 %) were taking antipsychotics, which was associated with male gender (p = 0.01), intellectual disability with and without autism spectrum disorder (p = 0.001 and p = 0.04, respectively), and inversely associated with the youngest and oldest age categories (p = 0.001 and p = 0.04, respectively). Among those taking antipsychotics, annual metabolic monitoring rates ranged from 89 % (lipids) to 99 % (weight). Age was positively associated with glucose (p < 0.001) and lipid monitoring (p < 0.001). Adult participants with dyslipidemia (p < 0.01), prediabetes/diabetes (p = 0.04), and hypertension (p = 0.02) were significantly more likely to obtain lipid monitoring. These values exceeded previously reported rates suggesting the importance of an integrated care model.
Literatuur
go back to reference Aman, M. G., Lam, K. L., & Van Bourgondien, M. E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15(1), 116–126.CrossRefPubMed Aman, M. G., Lam, K. L., & Van Bourgondien, M. E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15(1), 116–126.CrossRefPubMed
go back to reference Baburaj, R., & El Tahir, M. (2011). Monitoring for metabolic syndrome in people with intellectual disability on antipsychotic medication. Advances in Mental Health and Intellectual Disabilities, 5(3), 38–44.CrossRef Baburaj, R., & El Tahir, M. (2011). Monitoring for metabolic syndrome in people with intellectual disability on antipsychotic medication. Advances in Mental Health and Intellectual Disabilities, 5(3), 38–44.CrossRef
go back to reference Bansal, S., Buring, J., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007). Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Journal of American Medical Association, 298(3), 309–316.CrossRef Bansal, S., Buring, J., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007). Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Journal of American Medical Association, 298(3), 309–316.CrossRef
go back to reference Barnes, T. P. (2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme. Acta Psychiatrica Scandinavica, 118(1), 26–33.CrossRefPubMed Barnes, T. P. (2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: A quality improvement programme. Acta Psychiatrica Scandinavica, 118(1), 26–33.CrossRefPubMed
go back to reference Bhaumik, S. W. (2008). Body mass index in adults with intellectual disability: Distribution, associations and service implications: A population-based prevalence study. Journal of Intellectual Disability Research, 52(4), 287–298.CrossRefPubMed Bhaumik, S. W. (2008). Body mass index in adults with intellectual disability: Distribution, associations and service implications: A population-based prevalence study. Journal of Intellectual Disability Research, 52(4), 287–298.CrossRefPubMed
go back to reference Buck, T. R., Viskochil, J., Farley, M., Coon, H., McMahon, W. M., Morgan, J., & Bilder, D. A. (2014). Psychiatric comorbidity and medication use in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders, 44(12), 3063–3071.CrossRefPubMedPubMedCentral Buck, T. R., Viskochil, J., Farley, M., Coon, H., McMahon, W. M., Morgan, J., & Bilder, D. A. (2014). Psychiatric comorbidity and medication use in adults with autism spectrum disorder. Journal of Autism and Developmental Disorders, 44(12), 3063–3071.CrossRefPubMedPubMedCentral
go back to reference Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004). Journal of Clinical Psychiatry, 65(2), 267–272. doi:10.4088/JCP.v65n0219 Consensus development conference on antipsychotic drugs and obesity and diabetes. (2004). Journal of Clinical Psychiatry, 65(2), 267–272. doi:10.​4088/​JCP.​v65n0219
go back to reference Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., & Perrin, J. M. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(Suppl 2), S69–S76.CrossRefPubMed Coury, D. L., Anagnostou, E., Manning-Courtney, P., Reynolds, A., Cole, L., McCoy, R., & Perrin, J. M. (2012). Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics, 130(Suppl 2), S69–S76.CrossRefPubMed
go back to reference Devapriam, J., Anand, A., Raju, L., & Bhaumik, S. (2009). Monitoring for metabolic syndrome in adults with intellectual disability on atypical antipsychotic drugs. British Journal of Developmental Disabilities, 55(Part 1(108)), 3–13.CrossRef Devapriam, J., Anand, A., Raju, L., & Bhaumik, S. (2009). Monitoring for metabolic syndrome in adults with intellectual disability on atypical antipsychotic drugs. British Journal of Developmental Disabilities, 55(Part 1(108)), 3–13.CrossRef
go back to reference Eberly, L. E., Stamler, J., & Neaton, J. D. (2003). Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine, 163(1), 1077–1083.CrossRefPubMed Eberly, L. E., Stamler, J., & Neaton, J. D. (2003). Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Archives of Internal Medicine, 163(1), 1077–1083.CrossRefPubMed
go back to reference Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001). Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Research, 101(3), 277–288. doi:10.1016/S0165-1781(01)00234-7.CrossRefPubMed Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001). Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Research, 101(3), 277–288. doi:10.​1016/​S0165-1781(01)00234-7.CrossRefPubMed
go back to reference Frighi, V., Stephenson, M. T., Morovat, A., Jolley, I. E., Trivella, M., Dudley, C. A., & Goodwin, G. M. (2011). Safety of antipsychotics in people with intellectual disability. The British Journal of Psychiatry: The Journal of Mental Science, 199(4), 289–295. doi:10.1192/bjp.bp.110.085670.CrossRef Frighi, V., Stephenson, M. T., Morovat, A., Jolley, I. E., Trivella, M., Dudley, C. A., & Goodwin, G. M. (2011). Safety of antipsychotics in people with intellectual disability. The British Journal of Psychiatry: The Journal of Mental Science, 199(4), 289–295. doi:10.​1192/​bjp.​bp.​110.​085670.CrossRef
go back to reference Ghate, S. I. (2012). Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Mental Health In Family Medicine, 9(3), 137–148.PubMedPubMedCentral Ghate, S. I. (2012). Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Mental Health In Family Medicine, 9(3), 137–148.PubMedPubMedCentral
go back to reference Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry, 166(3), 345–353.CrossRefPubMed Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R., & Newcomer, J. W. (2009). Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. The American Journal of Psychiatry, 166(3), 345–353.CrossRefPubMed
go back to reference Hsu, C., Ried, L. D., Bengtson, M. A., Garman, P. M., McConkey, J. R., & Rahnavard, F. (2008). Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association: Japha, 48(3), 393–400. doi:10.1331/JAPhA.2008.07007.CrossRefPubMed Hsu, C., Ried, L. D., Bengtson, M. A., Garman, P. M., McConkey, J. R., & Rahnavard, F. (2008). Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. Journal of the American Pharmacists Association: Japha, 48(3), 393–400. doi:10.​1331/​JAPhA.​2008.​07007.CrossRefPubMed
go back to reference Koch, D. A., & Scott, A. J. (2012). Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: Comparisons for prescriptions administered using algorithms versus usual care. Journal of Psychiatric and Mental Health Nursing, 19(5), 389–394. doi:10.1111/j.1365-2850.2011.01781.x.CrossRefPubMed Koch, D. A., & Scott, A. J. (2012). Weight gain and lipid–glucose profiles among patients taking antipsychotic medications: Comparisons for prescriptions administered using algorithms versus usual care. Journal of Psychiatric and Mental Health Nursing, 19(5), 389–394. doi:10.​1111/​j.​1365-2850.​2011.​01781.​x.CrossRefPubMed
go back to reference Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine, 42(1), 125–147. doi:10.1017/S003329171100105X.CrossRefPubMed Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychological Medicine, 42(1), 125–147. doi:10.​1017/​S003329171100105​X.CrossRefPubMed
go back to reference Moeller, K. E., Rigler, S. K., Mayorga, A., Nazir, N., & Shireman, T. I. (2011). Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research, 126(1–3), 117–123. doi:10.1016/j.schres.2010.11.015.CrossRefPubMed Moeller, K. E., Rigler, S. K., Mayorga, A., Nazir, N., & Shireman, T. I. (2011). Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance. Schizophrenia Research, 126(1–3), 117–123. doi:10.​1016/​j.​schres.​2010.​11.​015.CrossRefPubMed
go back to reference Mukherjee, S., Schnur, D. B., & Reddy, F. (1989). Family history of type 2 diabetes in schizophrenia patients. Lancet, 1, 495.CrossRefPubMed Mukherjee, S., Schnur, D. B., & Reddy, F. (1989). Family history of type 2 diabetes in schizophrenia patients. Lancet, 1, 495.CrossRefPubMed
go back to reference Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007). Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Journal Of American Medical Association, 298(3), 299–308.CrossRef Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007). Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Journal Of American Medical Association, 298(3), 299–308.CrossRef
go back to reference Paton, C. T. (2011). Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. Journal of Intellectual Disability Research, 55(7), 665–674.CrossRefPubMed Paton, C. T. (2011). Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. Journal of Intellectual Disability Research, 55(7), 665–674.CrossRefPubMed
go back to reference Ryan, M. C., Collins, P., & Thakore, M. B. (2003). Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. American Journal of Psychiatry, 160(2), 284–289.CrossRefPubMed Ryan, M. C., Collins, P., & Thakore, M. B. (2003). Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. American Journal of Psychiatry, 160(2), 284–289.CrossRefPubMed
go back to reference Shi, L., Ascher-Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V., & Winstead, D. (2009). Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. doi:10.1186/1471-244X-9-80.PubMedPubMedCentral Shi, L., Ascher-Svanum, H., Chiang, Y., Zhao, Y., Fonseca, V., & Winstead, D. (2009). Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration. BMC Psychiatry. doi:10.​1186/​1471-244X-9-80.PubMedPubMedCentral
go back to reference Teeluckdharry, S., Sharma, S., O’Rourke, E., Tharian, P., Gondalekar, A., Nainar, F., & Roy, M. (2013). Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. Journal of Intellectual Disabilities, 17(3), 223–235. doi:10.1177/1744629513495261.CrossRefPubMed Teeluckdharry, S., Sharma, S., O’Rourke, E., Tharian, P., Gondalekar, A., Nainar, F., & Roy, M. (2013). Monitoring metabolic side effects of atypical antipsychotics in people with an intellectual disability. Journal of Intellectual Disabilities, 17(3), 223–235. doi:10.​1177/​1744629513495261​.CrossRefPubMed
go back to reference Tsiouris, J., Kim, S., Brown, W., Pettinger, J., & Cohen, I. (2013). Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders, 43(3), 719–731.CrossRefPubMed Tsiouris, J., Kim, S., Brown, W., Pettinger, J., & Cohen, I. (2013). Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large scale study. Journal of Autism and Developmental Disorders, 43(3), 719–731.CrossRefPubMed
go back to reference Weedon, D., Carbone, P., Bilder, D., O’Brien, S., & Dorius, J. (2012). Building a person-centered medical home: Lessons from a program for people with developmental disabilities. Journal of Health Care for the Poor and Underserved, 23(4), 1600–1608.CrossRefPubMed Weedon, D., Carbone, P., Bilder, D., O’Brien, S., & Dorius, J. (2012). Building a person-centered medical home: Lessons from a program for people with developmental disabilities. Journal of Health Care for the Poor and Underserved, 23(4), 1600–1608.CrossRefPubMed
go back to reference Wysokiński, A., Kowman, M., & Kłoszewska, I. (2012). The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics—a retrospective medical records review. Psychiatria Danubina, 24(3), 314–322.PubMed Wysokiński, A., Kowman, M., & Kłoszewska, I. (2012). The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics—a retrospective medical records review. Psychiatria Danubina, 24(3), 314–322.PubMed
Metagegevens
Titel
Antipsychotic Use and Metabolic Monitoring in Individuals with Developmental Disabilities Served in a Medicaid Medical Home
Auteurs
Lisa M. Ruiz
Mackenzie Damron
Kyle B. Jones
Dean Weedon
Paul S. Carbone
Amanda V. Bakian
Deborah A. Bilder
Publicatiedatum
27-01-2016
Uitgeverij
Springer US
Gepubliceerd in
Journal of Autism and Developmental Disorders / Uitgave 6/2016
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI
https://doi.org/10.1007/s10803-016-2712-x